了解念珠菌对唑类抗真菌药的抗性机制。

IF 3.7 Q2 INFECTIOUS DISEASES
JAC-Antimicrobial Resistance Pub Date : 2025-06-23 eCollection Date: 2025-06-01 DOI:10.1093/jacamr/dlaf106
Yunxiao Li, Charlotte Hind, Jessica Furner-Pardoe, J Mark Sutton, Khondaker Miraz Rahman
{"title":"了解念珠菌对唑类抗真菌药的抗性机制。","authors":"Yunxiao Li, Charlotte Hind, Jessica Furner-Pardoe, J Mark Sutton, Khondaker Miraz Rahman","doi":"10.1093/jacamr/dlaf106","DOIUrl":null,"url":null,"abstract":"<p><p>Cases of <i>Candida</i> infection have been on the rise in recent years. A comprehensive and clear understanding of the mechanisms of antifungal resistance is fundamental for developing novel therapies to address the current and emerging threat of fungal diseases. Certain <i>Candida</i> species can cause superficial or invasive infections in immunocompromised hosts, and invasive <i>Candida</i> infections are major contributors to infectious disease deaths. As fungi are eukaryotes like humans, there are only a limited number of unique molecular targets available for antifungal drug development. Until recently, there have only been four primary classes of antifungals used to treat systemic fungal infections. Among these, azole antifungals are globally used because they are both inexpensive and effective. Due to various factors, resistance to antifungal drugs-especially azole antifungals-has developed in many <i>Candida</i> species, posing a significant public health threat. This review discusses the known mechanisms of azole antifungal resistance in <i>Candida albicans</i>, <i>Candida auris</i>, <i>Nakaseomyces glabrata</i>, <i>Candida tropicalis</i>, <i>Candida parapsilosis</i> and explores strategies to overcome the resistance problem.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 3","pages":"dlaf106"},"PeriodicalIF":3.7000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205959/pdf/","citationCount":"0","resultStr":"{\"title\":\"Understanding the mechanisms of resistance to azole antifungals in <i>Candida</i> species.\",\"authors\":\"Yunxiao Li, Charlotte Hind, Jessica Furner-Pardoe, J Mark Sutton, Khondaker Miraz Rahman\",\"doi\":\"10.1093/jacamr/dlaf106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cases of <i>Candida</i> infection have been on the rise in recent years. A comprehensive and clear understanding of the mechanisms of antifungal resistance is fundamental for developing novel therapies to address the current and emerging threat of fungal diseases. Certain <i>Candida</i> species can cause superficial or invasive infections in immunocompromised hosts, and invasive <i>Candida</i> infections are major contributors to infectious disease deaths. As fungi are eukaryotes like humans, there are only a limited number of unique molecular targets available for antifungal drug development. Until recently, there have only been four primary classes of antifungals used to treat systemic fungal infections. Among these, azole antifungals are globally used because they are both inexpensive and effective. Due to various factors, resistance to antifungal drugs-especially azole antifungals-has developed in many <i>Candida</i> species, posing a significant public health threat. This review discusses the known mechanisms of azole antifungal resistance in <i>Candida albicans</i>, <i>Candida auris</i>, <i>Nakaseomyces glabrata</i>, <i>Candida tropicalis</i>, <i>Candida parapsilosis</i> and explores strategies to overcome the resistance problem.</p>\",\"PeriodicalId\":14594,\"journal\":{\"name\":\"JAC-Antimicrobial Resistance\",\"volume\":\"7 3\",\"pages\":\"dlaf106\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-06-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205959/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAC-Antimicrobial Resistance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jacamr/dlaf106\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlaf106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

近年来,念珠菌感染病例呈上升趋势。全面而清晰地了解抗真菌耐药性的机制是开发新疗法以解决当前和新出现的真菌疾病威胁的基础。某些念珠菌种类可在免疫功能低下的宿主中引起浅表或侵袭性感染,而侵袭性念珠菌感染是传染病死亡的主要原因。由于真菌和人类一样是真核生物,只有有限数量的独特分子靶点可用于抗真菌药物的开发。直到最近,只有四种主要的抗真菌药物用于治疗全身真菌感染。其中,唑类抗真菌药物因其价格低廉且有效而在全球广泛使用。由于各种因素的影响,许多念珠菌对抗真菌药物,特别是唑类抗真菌药物产生了耐药性,对公众健康构成了重大威胁。本文综述了目前已知的白色念珠菌、耳念珠菌、光秃中丝酵母、热带念珠菌、副假丝酵母对唑类真菌耐药的机制,并探讨了克服耐药问题的对策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Understanding the mechanisms of resistance to azole antifungals in Candida species.

Cases of Candida infection have been on the rise in recent years. A comprehensive and clear understanding of the mechanisms of antifungal resistance is fundamental for developing novel therapies to address the current and emerging threat of fungal diseases. Certain Candida species can cause superficial or invasive infections in immunocompromised hosts, and invasive Candida infections are major contributors to infectious disease deaths. As fungi are eukaryotes like humans, there are only a limited number of unique molecular targets available for antifungal drug development. Until recently, there have only been four primary classes of antifungals used to treat systemic fungal infections. Among these, azole antifungals are globally used because they are both inexpensive and effective. Due to various factors, resistance to antifungal drugs-especially azole antifungals-has developed in many Candida species, posing a significant public health threat. This review discusses the known mechanisms of azole antifungal resistance in Candida albicans, Candida auris, Nakaseomyces glabrata, Candida tropicalis, Candida parapsilosis and explores strategies to overcome the resistance problem.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信